Citadel Advisors
SYRE icon

Citadel Advisors’s Spyre Therapeutics SYRE Stock Holding History

Citadel Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,200
Closed -$51.6K – 15013
2025
Q1 		$51.6K Sell
3,200
-3,700
-54% -$77K ﹤0.01% 12282
2024
Q4 		$161K Buy
6,900
+6,300
+1,050% +$185K ﹤0.01% 10782
2024
Q3 		$17.6K Sell
600
-2,000
-77% -$55.7K ﹤0.01% 12874
2024
Q2 		$61.1K Buy
+2,600
New +$87.7K ﹤0.01% 11544
2024
Q1 		– Sell
-60
Closed -$1.29K – 15417
2023
Q4 		$1.29K Buy
60
+4
+7% +$55 ﹤0.01% 13854
2023
Q3 		$686 Buy
+56
New +$740 ﹤0.01% 14004
2023
Q1 		– Sell
-604
Closed -$6.79K – 15499
2022
Q4 		$6.79K Hold
604
– – ﹤0.01% 13883
2022
Q3 		$8K Sell
604
-1,164
-66% -$14.4K ﹤0.01% 12313
2022
Q2 		$22K Buy
+1,768
New +$62K ﹤0.01% 12368
2022
Q1 		– Sell
-1,268
Closed -$151K – 14549
2021
Q4 		$151K Buy
1,268
+860
+211% +$136K ﹤0.01% 12246
2021
Q3 		$81K Sell
408
-1,156
-74% -$202K ﹤0.01% 13063
2021
Q2 		$272K Sell
1,564
-128
-8% -$23.3K ﹤0.01% 11513
2021
Q1 		$335K Buy
+1,692
New +$325K ﹤0.01% 10577

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Citadel Advisors's SYRE Position: Q1 2026 in Review

Citadel Advisors increased its Spyre Therapeutics (SYRE) stake by 69% in Q1 2026, buying an estimated $1.67M and bringing the position to 108,135 shares worth $5.45M. The position accounts for ﹤0.01% of the portfolio, ranked #4206.

Citadel Advisors first reported a position in SYRE in Q2 2016 and has held it in 21 quarters since. The position peaked at $26.8M in Q1 2024. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Citadel Advisors held 108,135 shares of Spyre Therapeutics worth $5.45M as of Q1 2026.
  • Citadel Advisors bought 44,231 Spyre Therapeutics shares in Q1 2026, an estimated $1.67M.
  • Spyre Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4206 holding.
  • Citadel Advisors first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 21 quarters since.
  • Citadel Advisors's Spyre Therapeutics position peaked at $26.8M in Q1 2024.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.